{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:34:55Z","timestamp":1781530495638,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12325-019-01014-4","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T15:02:50Z","timestamp":1562338970000},"page":"2233-2246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson\u2019s Disease in the United States"],"prefix":"10.1007","volume":"36","author":[{"given":"Fahd","family":"Amjad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danish","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odinachi","family":"Oguh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Zamudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard Verhagen","family":"Metman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"key":"1014_CR1","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1038\/ctg.2016.19","volume":"7","author":"M Epstein","year":"2016","unstructured":"Epstein M, Johnson DA, Hawes R, Schmulewitz N, Vanagunas AD, Gossen ER, et al. Long-term PEG-J tube safety in patients with advanced Parkinson\u2019s disease. Clin Transl Gastroenterol. 2016;7:e159.","journal-title":"Clin Transl Gastroenterol."},{"issue":"2","key":"1014_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3233\/JPD-161042","volume":"7","author":"AA Othman","year":"2017","unstructured":"Othman AA, Rosebraugh M, Chatamra K, Locke C, Dutta S. Levodopa\u2013carbidopa intestinal gel pharmacokinetics: lower variability than oral levodopa\u2013carbidopa. J Parkinsons Dis. 2017;7(2):275\u20138.","journal-title":"J Parkinsons Dis."},{"issue":"1","key":"1014_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1531-8257(200001)15:1<3::AID-MDS1003>3.0.CO;2-E","volume":"15","author":"L Verghagen Metman","year":"2000","unstructured":"Verghagen Metman L, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson\u2019s disease: hypotheses on the why, where, and what. Mov Disord. 2000;15(1):3\u20138.","journal-title":"Mov Disord."},{"issue":"9","key":"1014_CR4","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1212\/WNL.43.9.1698","volume":"43","author":"MC Kurth","year":"1993","unstructured":"Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT, Goetz CG, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa\/carbidopa in Parkinson\u2019s disease patients with \u2018on-off\u2019 fluctuations. Neurology. 1993;43(9):1698\u2013703.","journal-title":"Neurology."},{"issue":"2","key":"1014_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","volume":"64","author":"D Nyholm","year":"2005","unstructured":"Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64(2):216\u201323.","journal-title":"Neurology."},{"issue":"2","key":"1014_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa\u2013carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol."},{"issue":"3","key":"1014_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.parkreldis.2014.12.012","volume":"21","author":"A Antonini","year":"2015","unstructured":"Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, Gloria Study Investigators. Global long-term study on motor and non-motor symptoms and safety of levodopa\u2013carbidopa intestinal gel in routine care of advanced Parkinson\u2019s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21(3):231\u20135.","journal-title":"Parkinsonism Relat Disord."},{"issue":"4","key":"1014_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, et al. Levodopa\u2013carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results. Mov Disord. 2015;30(4):500\u20139.","journal-title":"Mov Disord"},{"issue":"1","key":"1014_CR9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/JPD-140456","volume":"5","author":"JT Slevin","year":"2015","unstructured":"Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, et al. Long-term safety and maintenance of efficacy of levodopa\u2013carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson\u2019s disease patients. J Parkinsons Dis. 2015;5(1):165\u201374.","journal-title":"J Parkinsons Dis."},{"issue":"6","key":"1014_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mdc3.12526","volume":"4","author":"DG Standaert","year":"2017","unstructured":"Standaert DG, Rodriguez RL, Slevin JT, Lobatz M, Eaton S, Chatamra K, et al. Effect of levodopa\u2013carbidopa intestinal gel on non-motor symptoms in patients with advanced Parkinson\u2019s disease. Mov Disord Clin Pract. 2017;4(6):829\u201337.","journal-title":"Mov Disord Clin Pract."},{"key":"1014_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtosek Z, et al. Levodopa\u2013carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13\u201320.","journal-title":"Parkinsonism Relat Disord."},{"issue":"7","key":"1014_CR12","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s12325-017-0571-2","volume":"34","author":"R Kruger","year":"2017","unstructured":"Kruger R, Lingor P, Doskas T, Henselmans JML, Danielsen EH, de Fabregues O, et al. An observational study of the effect of levodopa\u2013carbidopa intestinal gel on activities of daily living and quality of life in advanced Parkinson\u2019s disease patients. Adv Ther. 2017;34(7):1741\u201352.","journal-title":"Adv Ther."},{"issue":"8","key":"1014_CR13","doi-asserted-by":"publisher","first-page":"e00758","DOI":"10.1002\/brb3.758","volume":"7","author":"O De Fabregues","year":"2017","unstructured":"De Fabregues O, Dot J, Abu-Suboh M, Hernandez-Vara J, Ferre A, Romero O, et al. Long-term safety and effectiveness of levodopa\u2013carbidopa intestinal gel infusion. Brain Behav. 2017;7(8):e00758.","journal-title":"Brain Behav."},{"issue":"10","key":"1014_CR14","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.parkreldis.2015.07.020","volume":"21","author":"P Odin","year":"2015","unstructured":"Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson\u2019s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21(10):1133\u201344.","journal-title":"Parkinsonism Relat Disord."},{"issue":"Suppl 2","key":"1014_CR15","first-page":"S287","volume":"32","author":"P Dowell","year":"2017","unstructured":"Dowell P, Lyons K, Pahwa R. Clinical experience with initiation of carbidopa\/levodopa enteral suspension in Parkinson\u2019s disease patients with cognitive impairment. Mov Disord. 2017;32(Suppl 2):S287.","journal-title":"Mov Disord."},{"issue":"4","key":"1014_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/mds.26195","volume":"30","author":"A Fasano","year":"2015","unstructured":"Fasano A, Liu LW, Poon YY, Lang AE. Initiating intrajejunal infusion of levodopa\/carbidopa intestinal gel: an outpatient model. Mov Disord. 2015;30(4):598\u20139.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"1014_CR17","first-page":"S93","volume":"33","author":"J Aldred","year":"2018","unstructured":"Aldred J, Davis T, Zamudio J, Kukreja P, Bergmann L, Li M, et al. Titration of levodopa\u2013carbidopa intestinal gel in US patients with advanced Parkinson\u2019s disease. Mov Disord. 2018;33(Suppl 1):S93.","journal-title":"Mov Disord"},{"issue":"8","key":"1014_CR18","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.parkreldis.2015.05.018","volume":"21","author":"P Solla","year":"2015","unstructured":"Solla P, Fasano A, Cannas A, Mulas CS, Marrosu MG, Lang AE, et al. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson\u2019s disease patients treated with levodopa\u2013carbidopa intestinal gel infusion. Parkinsonism Relat Disord. 2015;21(8):968\u201371.","journal-title":"Parkinsonism Relat Disord."},{"issue":"7","key":"1014_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.parkreldis.2015.04.022","volume":"21","author":"MF Lew","year":"2015","unstructured":"Lew MF, Slevin JT, Kruger R, Martinez Castrillo JC, Chatamra K, Dubow JS, et al. Initiation and dose optimization for levodopa\u2013carbidopa intestinal gel: insights from phase 3 clinical trials. Parkinsonism Relat Disord. 2015;21(7):742\u20138.","journal-title":"Parkinsonism Relat Disord."},{"issue":"Suppl","key":"1014_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jns.2017.08.525","volume":"381","author":"JT Boyd","year":"2017","unstructured":"Boyd JT, Zadikoff C, Benesh JA, Zamudio J, Robieson WZ, Kukreja P. Safety and efficacy of levodopa\u2013carbidopa monotherapy in patients with advanced Parkinson\u2019s disease. J Neuro Sci. 2017;381(Suppl):182\u20133.","journal-title":"J Neuro Sci."},{"issue":"3","key":"1014_CR21","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","volume":"91","author":"JC Corvol","year":"2018","unstructured":"Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91(3):e189\u2013201.","journal-title":"Neurology."},{"issue":"6","key":"1014_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00415-018-8803-1","volume":"265","author":"MJ Catalan","year":"2018","unstructured":"Catalan MJ, Molina-Arjona JA, Mir P, Cubo E, Arbelo JM, Martinez-Martin P, et al. Improvement of impulse control disorders associated with levodopa\u2013carbidopa intestinal gel treatment in advanced Parkinson\u2019s disease. J Neurol. 2018;265(6):1279\u201387.","journal-title":"J Neurol"},{"issue":"5","key":"1014_CR23","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/ana.20822","volume":"59","author":"AH Evans","year":"2006","unstructured":"Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006;59(5):852\u20138.","journal-title":"Ann Neurol"},{"issue":"15","key":"1014_CR24","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord. 2010;25(15):2649\u201353.","journal-title":"Mov Disord"},{"issue":"5","key":"1014_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/00207454.2016.1193862","volume":"127","author":"R Pahwa","year":"2017","unstructured":"Pahwa R, Lyons KE. Outpatient titration of carbidopa\/levodopa enteral suspension (Duopa). Int J Neurosci. 2017;127(5):459\u201365.","journal-title":"Int J Neurosci"},{"key":"1014_CR26","unstructured":"Duopa (carbidopa and levodopa) enteral suspension [prescribing information]. North Chicago: AbbVie Inc. 2016. \n                    https:\/\/www.rxabbvie.com\/pdf\/duopa_pi.pdf\n                    \n                  ."},{"issue":"4","key":"1014_CR27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3233\/JPD-161048","volume":"7","author":"T Willows","year":"2017","unstructured":"Willows T, Dizdar N, Nyholm D, Widner H, Grenholm P, Schmiauke U, et al. Initiation of levodopa\u2013carbidopa intestinal gel infusion using telemedicine (video communication system) facilitates efficient and well-accepted home titration in patients with advanced Parkinson\u2019s disease. J Parkinsons Dis. 2017;7(4):719\u201328.","journal-title":"J Parkinsons Dis."},{"issue":"12","key":"1014_CR28","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1002\/mds.23833","volume":"26","author":"F Klostermann","year":"2011","unstructured":"Klostermann F, Jugel C, Marzinzik F. Jejunal levodopa infusion in long-term DBS patients with Parkinson\u2019s disease. Mov Disord. 2011;26(12):2298\u20139.","journal-title":"Mov Disord"},{"key":"1014_CR29","unstructured":"Burack MA, Santiago A, Biglan K, Barbano R. Levodopa\u2013carbidopa intestinal gel therapy (LCIG) choices and clinical outcomes in DBS-eligible versus palliative stage PD patients. Parkinson Study Group Annual Meeting; September 17\u201319; Portland, Oregon; 2016."},{"issue":"2","key":"1014_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/mds.27211","volume":"33","author":"N Kumar","year":"2018","unstructured":"Kumar N, Murgai A, Naranian T, Jog M, Fasano A. Levodopa\u2013carbidopa intestinal gel therapy after deep brain stimulation. Mov Disord. 2018;33(2):334\u20135.","journal-title":"Mov Disord"},{"issue":"3","key":"1014_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/WNF.0000000000000216","volume":"40","author":"I Regidor","year":"2017","unstructured":"Regidor I, Benita V, de Pedro MD, Ley L, Martinez Castrillo JC. Duodenal levodopa infusion for long-term deep brain stimulation-refractory symptoms in advanced Parkinson disease. Clin Neuropharmacol. 2017;40(3):103\u20137.","journal-title":"Clin Neuropharmacol."},{"issue":"Suppl 2","key":"1014_CR32","first-page":"S189","volume":"31","author":"RL Blaze","year":"2016","unstructured":"Blaze RL, Tan J, Evans AH. Quantitative assessment of advanced therapies in Parkinson\u2019s disease using the Parkinson kinetigraph (PKG). Mov Disord. 2016;31(Suppl 2):S189.","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"1014_CR33","first-page":"S267","volume":"32","author":"J Margolesky","year":"2017","unstructured":"Margolesky J, Luca C. Personal KinetiGraph devices assessing efficacy of continuous enteral carbidopa\/levodopa infusion therapy. Mov Disord. 2017;32(Suppl 2):S267.","journal-title":"Mov Disord"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01014-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01014-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01014-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T23:06:07Z","timestamp":1593817567000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01014-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1014"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01014-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,5]]},"assertion":[{"value":"27 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}